Merck Shares Update on Phase 3 Trial KeyVibe-008 Testing Vibostolimab and Pembrolizumab Combo in Extensive-Stage Small Cell Lung Cancer.

Novartis gets FDA fast-track approval for Fabhalta® (iptacopan), marking it as the inaugural complement inhibitor to lower proteinuria in primary IgA nephropathy (IgAN).

Invenra Showcases Exelixis’ News: Phase 1 Clinical Trial Begins for XB010 in Advanced Solid Tumor Patients.

This study is assessing the safety and tolerability of MTX-474, a human IgG1 antibody created to inhibit EphrinB2 signaling.

Takeda Gains European Commission Clearance for ADZYNMA (Recombinant ADAMTS13), the First Recombinant ADAMTS13 Therapy for cTTP.

The FDA has approved Servier's VORANIGO® (vorasidenib) tablets as the first targeted treatment for Grade 2 IDH-mutant glioma.

NeuroBo Pharmaceuticals, Dong-A ST, and ImmunoForge Sign Agreement to Collaborate on Developing a Monthly DA-1726 Formulation to Treat Obesity.

The initial participant in the U.S. joins the phase III global multi-center clinical trial for telitacicept targeting myasthenia gravis, marking a significant milestone.

Elevation Oncology Releases Encouraging Early Results from Phase 1 Trial of EO-3021 in Patients with Advanced Non-Resectable or Metastatic Solid Tumors.

This expansion now encompasses Merck’s investigational product MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).

Equillium Reports Favorable Interim Results from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease.

Global pharma major Lupin Limited, revealed the introduction of its first biosimilar in Canada, Rymti®, via its collaborator, Sandoz Canada.